Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All ambavirumab studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAmbavirumab/romlusevimabAmbavir../r.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort study

Yalan et al., BMC Pharmacology and Toxicology, doi:10.1186/s40360-024-00753-7
Apr 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality -71% Improvement Relative Risk ICU admission -8% Hospitalization time 8% Time to viral- 7% Ambavirumab/r..  Yalan et al.  LATE TREATMENT Is late treatment with ambavirumab beneficial for COVID-19? Retrospective 340 patients in China (October - November 2022) Shorter hospitalization (p=0.004) and faster viral clearance (p=0.004) c19early.org Yalan et al., BMC Pharmacology and Tox.., Apr 2024 Favorsambavirumab Favorscontrol 0 0.5 1 1.5 2+
Retrospective 340 COVID-19 patients in China showing shorter length of hospital stay and faster viral clearance with BRII-196 plus BRII-198 monoclonal antibody treatment, especially when given early. The treatment did not show efficacy for improving clinical outcomes among severe or critical cases.
Efficacy is variant dependent.
Viral load measured by PCR may not accurately reflect infectious virus measured by viral culture. Porter et al. show that viral load early in infection was correlated with infectious virus, but viral load late in infection could be high even with low or undetectable infectious virus. Assessing viral load later in infection may underestimate reductions in infectious virus with treatment.
This study is excluded in the after exclusion results of meta analysis: unadjusted differences between groups.
risk of death, 71.4% higher, RR 1.71, p = 0.35, treatment 12 of 170 (7.1%), control 7 of 170 (4.1%).
risk of ICU admission, 7.7% higher, RR 1.08, p = 0.80, treatment 42 of 170 (24.7%), control 39 of 170 (22.9%).
hospitalization time, 7.7% lower, relative time 0.92, p = 0.004, treatment 170, control 170.
time to viral-, 6.7% lower, relative time 0.93, p = 0.004, treatment 170, control 170.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Yalan et al., 19 Apr 2024, retrospective, China, peer-reviewed, median age 72.0, 6 authors, study period October 2022 - November 2022. Contact: zhang.jj@vip.163.com, 300704@hospital.cqmu.edu.cn.
This PaperAmbavir../r..All
Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort study
MD Qin Yalan, Hao Lingfang, Liu Xisong, Liang Run, Zhang Junjing, Zhang’ An
BMC Pharmacology and Toxicology, doi:10.1186/s40360-024-00753-7
Background Monoclonal antibody therapy for Covid-19 springs up all over the world and get some efficiency. This research aims to explore the treating effect of plus on Covid-19. Methods In this retrospective cohort research, patients received standard care or plus BRII-196 /BRII-198 monoclonal antibodies. General comparison of clinical indexes and prognosis between Antibody Group and Control Group was made. Further, according to the antibody using time and patients' condition, subgroups included Early antibody group, Late antibody group, Mild Antibody Group, Mild Control Group, Severe Antibody Group and Severe Control Group. Results Length of stay(LOS) and interval of Covid-19 nucleic acid from positive to negative of Antibody Group were 12.0(IQR 9.0-15.0) and 14.0(IQR 10.0-16.0) days, less than those(13.0 (IQR 11.0-18.0) and 15.0 (IQR 12.8-17.0) days) of Control Group(p = 0.004, p = 0.004). LOS(median 10days) of Early Antibody Group was the shortest, significantly shorter than that of Control Group (median 13days)(p < 0.001). Interval(median 12days) of Covid-19 nucleic acid from positive to negative of Early Antibody Group also was significantly shorter than that of Control Group(median 15days) and Late Antibody Group(median 14days)(p = 0.001, p = 0.042). LOS(median 12days) and interval(median 13days) of Covid-19 nucleic acid from positive to negative of Mild Antibody Group was shorter than that of Mild Control Group(median 13days; median 14.5days)(p = 0.018, p = 0.033). Conclusion The neutralizing antibody therapy, BRII-196 plus BRII-198 could shorten LOS and interval of Covid-19 nucleic acid from positive to negative. However, it didn't show efficacy for improving clinical outcomes among severe or critical cases.
Supplementary Information The online version contains supplementary material available at https://doi. org/10.1186/s40360-024-00753-7. Supplementary Material 1 Author contributions Qin Yalan analyzed and interpreted the patient data and composed the manuscript. Hao Lingfang, Liang Run and Liu Xisong collected the clinical data. Zhang' An and Zhang Junjing came up with the research idea and revised the manuscript. All authors read and approved the final manuscript. Funding The research was supported by the Chongqing Special Research Project for Novel Coronavirus Pneumonia Prevention and Control, No.csct2020jscx-fyzxX0012. Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate The study was followed in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional Competing interests The authors declare no competing interests. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
Araf, Akter, Tang, Omicron variant of SARS-CoV-2: genomics, transmissibility, and responses to current COVID-19 vaccines, J Med Virol
Baum, Ajithdoss, Copin, REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters, Science
Evering, Mark, Chew, Safety and efficacy of combination SARS-CoV-2 monoclonal neutralizing antibodies (mAb) BRII-196 and BRII-198 in non-hospitalized COVID-19 patients, Open Forum Infect Di
Focosi, Maggi, Neutralising antibody escape of SARS-CoV-2 spike protein: risk assessment for antibody-based Covid-19 therapeutics and vaccines, Rev Med Virol
García-Lledó, Gómez-Pavón, González, Castillo, Pharmacological treatment of COVID-19: an opinion paper, Rev Esp Quimioter
Ge, Wang, Ju, Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry, Nat Commun
Gioacchino, Tonacci, Musolino, Gangemi, Immunopathology of SARS-CoV-2 infection: immune cells and mediators, prognostic factors, and immune-therapeutic implications, Int J Mol Sci
Gupta, Gonzalez-Rojas, Juarez, Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab, N Engl J Med
Hanaei, Rezaei, COVID-19: developing from an outbreak to a pandemic, Arch Med Res
Horby, Lim, Emberson, Dexamethasone in hospitalized patients with COVID-19, N Engl J Med
Hoy, Amubarvimab/Romlusevimab: first approval, Drugs
Huang, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Jones, Brown-Augsburger, Corbett, The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates, Sci Transl Med
Ju, Zhang, Ge, Human neutralizing antibodies elicited by SARS-CoV-2 infection, Nature
Kim, Jang, Hong, Safety, virologic efficacy, and pharmacokinetics of CT-P59, a neutralizing monoclonal antibody against SARS-CoV-2 spike receptor-binding protein: two randomized, placebo-controlled, phase I studies in healthy individuals and patients with mild SARS-CoV-2 infection, Clin Ther
Ling, Yi, Sun, Yang, Sun, Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies, Sci China Life Sci
Mittal, Manjunath, Ranjan, COVID-19 pandemic: insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2, PLoS Pathog
Senefeld, Franchini, Mengoli, COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta-analysis, JAMA Netw Open
Seo, Kang, Song, Preclinical assessment and randomized phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Emerg Microbes Infect
Sisi, Ruoke, Qi, Linqi, Ambavirumab injection (BRII-196) and Romisisimab injection (BRII-198): China's first independent intellectual property rights of neutralization and antibody combined therapy for COVID-19, J]. Chin J Med
{ 'indexed': {'date-parts': [[2024, 4, 20]], 'date-time': '2024-04-20T00:28:59Z', 'timestamp': 1713572939229}, 'reference-count': 22, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2024, 4, 19]], 'date-time': '2024-04-19T00:00:00Z', 'timestamp': 1713484800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2024, 4, 19]], 'date-time': '2024-04-19T00:00:00Z', 'timestamp': 1713484800000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'funder': [ { 'name': 'Chongqing Special Research Project for Novel Coronavirus Pneumonia Prevention and ' 'Control', 'award': ['No.csct2020jscx-fyzxX0012']}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'abstract': '<jats:title>Abstract</jats:title><jats:sec>\n' ' <jats:title>Background</jats:title>\n' ' <jats:p>Monoclonal antibody therapy for Covid-19 springs up all over the ' 'world and get some efficiency. This research aims to explore the treating effect of ' 'BRII-196(Ambavirumab) plus BRII-198(Lomisivir) on Covid-19.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Methods</jats:title>\n' ' <jats:p>In this retrospective cohort research, patients received standard ' 'care or plus BRII-196 /BRII-198 monoclonal antibodies. General comparison of clinical indexes ' 'and prognosis between Antibody Group and Control Group was made. Further, according to the ' 'antibody using time and patients’ condition, subgroups included Early antibody group, Late ' 'antibody group, Mild Antibody Group, Mild Control Group, Severe Antibody Group and Severe ' 'Control Group.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Results</jats:title>\n' ' <jats:p>Length of stay(LOS) and interval of Covid-19 nucleic acid from ' 'positive to negative of Antibody Group were 12.0(IQR 9.0–15.0) and 14.0(IQR 10.0–16.0) days, ' 'less than those(13.0 (IQR 11.0–18.0) and 15.0 (IQR 12.8–17.0) days) of Control ' 'Group(<jats:italic>p</jats:italic>\u2009=\u20090.004, <jats:italic>p</jats:italic>\u2009' '=\u20090.004). LOS(median 10days) of Early Antibody Group was the shortest, significantly ' 'shorter than that of Control Group (median 13days)(<jats:italic>p</jats:italic>\u2009' '&lt;\u20090.001). Interval(median 12days) of Covid-19 nucleic acid from positive to negative ' 'of Early Antibody Group also was significantly shorter than that of Control Group(median ' '15days) and Late Antibody Group(median 14days)(<jats:italic>p</jats:italic>\u2009=\u2009' '0.001, <jats:italic>p</jats:italic>\u2009=\u20090.042). LOS(median 12days) and ' 'interval(median 13days) of Covid-19 nucleic acid from positive to negative of Mild Antibody ' 'Group was shorter than that of Mild Control Group(median 13days; median ' '14.5days)(<jats:italic>p</jats:italic>\u2009=\u20090.018, <jats:italic>p</jats:italic>\u2009' '=\u20090.033).</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Conclusion</jats:title>\n' ' <jats:p>The neutralizing antibody therapy, BRII-196 plus BRII-198 could ' 'shorten LOS and interval of Covid-19 nucleic acid from positive to negative. However, it ' 'didn’t show efficacy for improving clinical outcomes among severe or critical ' 'cases.</jats:p>\n' ' </jats:sec>', 'DOI': '10.1186/s40360-024-00753-7', 'type': 'journal-article', 'created': {'date-parts': [[2024, 4, 19]], 'date-time': '2024-04-19T10:01:45Z', 'timestamp': 1713520905000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus ' 'BRII-198(Lomisivir): a retrospective cohort study', 'prefix': '10.1186', 'volume': '25', 'author': [ {'given': 'Qin', 'family': 'Yalan', 'sequence': 'first', 'affiliation': []}, {'given': 'Hao', 'family': 'Lingfang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Liu', 'family': 'Xisong', 'sequence': 'additional', 'affiliation': []}, {'given': 'Liang', 'family': 'Run', 'sequence': 'additional', 'affiliation': []}, {'given': 'Zhang', 'family': 'Junjing', 'sequence': 'additional', 'affiliation': []}, {'given': 'Zhang’', 'family': 'An', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2024, 4, 19]]}, 'reference': [ { 'key': '753_CR1', 'doi-asserted-by': 'publisher', 'first-page': '582', 'DOI': '10.1016/j.arcmed.2020.04.021', 'volume': '51', 'author': 'S Hanaei', 'year': '2020', 'unstructured': 'Hanaei S, Rezaei N. COVID-19: developing from an outbreak to a pandemic. ' 'Arch Med Res. 2020;51:582–4.', 'journal-title': 'Arch Med Res'}, { 'issue': '10223', 'key': '753_CR2', 'doi-asserted-by': 'publisher', 'first-page': '497', 'DOI': '10.1016/S0140-6736(20)30183-5', 'volume': '395', 'author': 'C Huang', 'year': '2020', 'unstructured': 'Huang C, et al. Clinical features of patients infected with 2019 novel ' 'coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.', 'journal-title': 'Lancet'}, { 'issue': '5', 'key': '753_CR3', 'doi-asserted-by': 'publisher', 'first-page': '1825', 'DOI': '10.1002/jmv.27588', 'volume': '94', 'author': 'Y Araf', 'year': '2022', 'unstructured': 'Araf Y, Akter F, Tang YD, et al. Omicron variant of SARS-CoV-2: ' 'genomics, transmissibility, and responses to current COVID-19 vaccines. ' 'J Med Virol. 2022;94(5):1825–32.', 'journal-title': 'J Med Virol'}, { 'issue': '1', 'key': '753_CR4', 'doi-asserted-by': 'publisher', 'first-page': 'e2250647', 'DOI': '10.1001/jamanetworkopen.2022.50647', 'volume': '6', 'author': 'JW Senefeld', 'year': '2023', 'unstructured': 'Senefeld JW, Franchini M, Mengoli C, et al. COVID-19 convalescent plasma ' 'for the treatment of immunocompromised patients: a systematic review and ' 'meta-analysis. JAMA Netw Open. 2023;6(1):e2250647.', 'journal-title': 'JAMA Netw Open'}, { 'key': '753_CR5', 'doi-asserted-by': 'publisher', 'first-page': '693', 'DOI': '10.1056/NEJMoa2021436', 'volume': '384', 'author': 'P Horby', 'year': '2021', 'unstructured': 'Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized ' 'patients with COVID-19. N Engl J Med. 2021;384:693–704.', 'journal-title': 'N Engl J Med'}, { 'issue': '2', 'key': '753_CR6', 'doi-asserted-by': 'publisher', 'first-page': '115', 'DOI': '10.37201/req/158.2021', 'volume': '35', 'author': 'A García-Lledó', 'year': '2022', 'unstructured': 'García-Lledó A, Gómez-Pavón J, González D, Castillo J, et al. ' 'Pharmacological treatment of COVID-19: an opinion paper. Rev Esp ' 'Quimioter. 2022;35(2):115–30.', 'journal-title': 'Rev Esp Quimioter'}, { 'issue': '6', 'key': '753_CR7', 'doi-asserted-by': 'publisher', 'first-page': 'e2231', 'DOI': '10.1002/rmv.2231', 'volume': '31', 'author': 'D Focosi', 'year': '2021', 'unstructured': 'Focosi D, Maggi F. Neutralising antibody escape of SARS-CoV-2 spike ' 'protein: risk assessment for antibody-based Covid-19 therapeutics and ' 'vaccines. Rev Med Virol. 2021;31(6):e2231.', 'journal-title': 'Rev Med Virol'}, { 'issue': '1', 'key': '753_CR8', 'doi-asserted-by': 'publisher', 'first-page': '250', 'DOI': '10.1038/s41467-020-20501-9', 'volume': '12', 'author': 'J Ge', 'year': '2021', 'unstructured': 'Ge J, Wang R, Ju B, et al. Antibody neutralization of SARS-CoV-2 through ' 'ACE2 receptor mimicry. Nat Commun. 2021;12(1):250.', 'journal-title': 'Nat Commun'}, { 'issue': '13', 'key': '753_CR9', 'doi-asserted-by': 'publisher', 'first-page': '4782', 'DOI': '10.3390/ijms21134782', 'volume': '21', 'author': 'A Allegra', 'year': '2020', 'unstructured': 'Allegra A, Di Gioacchino M, Tonacci A, Musolino C, Gangemi S. ' 'Immunopathology of SARS-CoV-2 infection: immune cells and mediators, ' 'prognostic factors, and immune-therapeutic implications. Int J Mol Sci. ' '2020;21(13):4782.', 'journal-title': 'Int J Mol Sci'}, { 'key': '753_CR10', 'doi-asserted-by': 'crossref', 'unstructured': 'Ling Z, Yi C, Sun X, Yang Z, Sun B. Broad strategies for neutralizing ' 'SARS-CoV-2 and other human coronaviruses with monoclonal antibodies. Sci ' 'China Life Sci. 2022:1–21.', 'DOI': '10.1007/s11427-022-2215-6'}, { 'key': '753_CR11', 'unstructured': 'Sisi S, Ruoke W, Qi Z. Zhang Linqi.Ambavirumab injection (BRII-196) and ' 'Romisisimab injection (BRII-198): China’s first independent intellectual ' 'property rights of neutralization and antibody combined therapy for ' 'COVID-19 [J]. Chin J Med. 2022,24(01):2–8.'}, { 'key': '753_CR12', 'unstructured': 'National Health Commission of China. New coronavirus pneumonia ' 'prevention and control program(9th ed). China Med,2022(04):481–7.'}, { 'issue': '8', 'key': '753_CR13', 'doi-asserted-by': 'publisher', 'first-page': 'e1008762', 'DOI': '10.1371/journal.ppat.1008762', 'volume': '16', 'author': 'A Mittal', 'year': '2020', 'unstructured': 'Mittal A, Manjunath K, Ranjan RK, et al. COVID-19 pandemic: insights ' 'into structure, function, and hACE2 receptor recognition by SARS-CoV-2. ' 'PLoS Pathog. 2020;16(8):e1008762.', 'journal-title': 'PLoS Pathog'}, { 'key': '753_CR14', 'doi-asserted-by': 'publisher', 'first-page': '115', 'DOI': '10.1038/s41586-020-2380-z', 'volume': '584', 'author': 'B Ju', 'year': '2020', 'unstructured': 'Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by ' 'SARS-CoV-2 infection. Nature. 2020;584:115–19.', 'journal-title': 'Nature'}, { 'issue': '10', 'key': '753_CR15', 'doi-asserted-by': 'publisher', 'first-page': '1706', 'DOI': '10.1016/j.clinthera.2021.08.009', 'volume': '43', 'author': 'JY Kim', 'year': '2021', 'unstructured': 'Kim JY, Jang YR, Hong JH, et al. Safety, virologic efficacy, and ' 'pharmacokinetics of CT-P59, a neutralizing monoclonal antibody against ' 'SARS-CoV-2 spike receptor-binding protein: two randomized, ' 'placebo-controlled, phase I studies in healthy individuals and patients ' 'with mild SARS-CoV-2 infection. Clin Ther. 2021;43(10):1706–27.', 'journal-title': 'Clin Ther'}, { 'issue': '12', 'key': '753_CR16', 'first-page': '1327', 'volume': '82', 'author': 'SM Hoy', 'year': '2022', 'unstructured': 'Hoy SM. Amubarvimab/Romlusevimab: first approval. Drugs. ' '2022;82(12):1327–31.', 'journal-title': 'First Approval Drugs'}, { 'issue': '5', 'key': '753_CR17', 'doi-asserted-by': 'publisher', 'first-page': '622', 'DOI': '10.1016/S1473-3099(21)00751-9', 'volume': '22', 'author': 'ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group', 'year': '2022', 'unstructured': 'ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group. ' 'Efficacy and safety of two neutralising monoclonal antibody therapies, ' 'sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with ' 'COVID-19 (TICO): a randomised controlled trial. Lancet Infect Dis. ' '2022;22(5):622–35.', 'journal-title': 'Lancet Infect Dis'}, { 'key': '753_CR18', 'doi-asserted-by': 'crossref', 'unstructured': 'Evering TH, Mark G, Chew KW, et al. LB2. Safety and efficacy of ' 'combination SARS-CoV-2 monoclonal neutralizing antibodies (mAb) BRII-196 ' 'and BRII-198 in non-hospitalized COVID-19 patients[J]. Open Forum Infect ' 'Di. 2021.', 'DOI': '10.1093/ofid/ofab466.1643'}, { 'issue': '1', 'key': '753_CR19', 'doi-asserted-by': 'publisher', 'first-page': '2315', 'DOI': '10.1080/22221751.2022.2117094', 'volume': '11', 'author': 'JM Seo', 'year': '2022', 'unstructured': 'Seo JM, Kang B, Song R, et al. Preclinical assessment and randomized ' 'phase I study of CT-P63, a broadly neutralizing antibody targeting ' 'severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Emerg ' 'Microbes Infect. 2022;11(1):2315–25.', 'journal-title': 'Emerg Microbes Infect'}, { 'key': '753_CR20', 'doi-asserted-by': 'publisher', 'first-page': 'eabf1906', 'DOI': '10.1126/scitranslmed.abf1906', 'volume': '13', 'author': 'BE Jones', 'year': '2021', 'unstructured': 'Jones BE, Brown-Augsburger PL, Corbett KS, et al. The neutralizing ' 'antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman ' 'primates. Sci Transl Med. 2021;13:eabf1906.', 'journal-title': 'Sci Transl Med'}, { 'key': '753_CR21', 'doi-asserted-by': 'publisher', 'first-page': '1110', 'DOI': '10.1126/science.abe2402', 'volume': '370', 'author': 'A Baum', 'year': '2020', 'unstructured': 'Baum A, Ajithdoss D, Copin R, et al. REGN-COV2 antibodies prevent and ' 'treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science. ' '2020;370:1110–5.', 'journal-title': 'Science'}, { 'issue': '21', 'key': '753_CR22', 'doi-asserted-by': 'publisher', 'first-page': '1941', 'DOI': '10.1056/NEJMoa2107934', 'volume': '385', 'author': 'A Gupta', 'year': '2021', 'unstructured': 'Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for Covid-19 ' 'with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. ' '2021;385(21):1941–50.', 'journal-title': 'N Engl J Med'}], 'container-title': 'BMC Pharmacology and Toxicology', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1186/s40360-024-00753-7.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1186/s40360-024-00753-7/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1186/s40360-024-00753-7.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 4, 19]], 'date-time': '2024-04-19T10:05:29Z', 'timestamp': 1713521129000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/s40360-024-00753-7'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 4, 19]]}, 'references-count': 22, 'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2024, 12]]}}, 'alternative-id': ['753'], 'URL': 'http://dx.doi.org/10.1186/s40360-024-00753-7', 'relation': {}, 'ISSN': ['2050-6511'], 'subject': [], 'container-title-short': 'BMC Pharmacol Toxicol', 'published': {'date-parts': [[2024, 4, 19]]}, 'assertion': [ { 'value': '15 July 2023', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '10 April 2024', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '19 April 2024', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, {'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}}, { 'value': 'The study was followed in accordance with the ethical standards of the ' 'responsible committee on human experimentation (institutional or regional) and ' 'with the Helsinki Declaration of 1975. The medical research record number is ' 'MR-50-20-002145 obtained from National Medical Research Registration and Filing ' 'System. Informed consent was obtained from all subjects or their legal ' 'guardians. The study was approved by the Hohhot First Hospital Research Ethics ' 'Commission on September 25th, 2022. Meanwhile it was also approved by Chongqing ' 'Public Health Treatment Center Research Ethics Commission.', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Ethics approval and consent to participate'}}, { 'value': 'NA.', 'order': 3, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Consent for publication'}}, { 'value': 'The authors declare no competing interests.', 'order': 4, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}], 'article-number': '29'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit